Full Year 2025 Basilea Pharmaceutica AG Allschwil Earnings Call Transcript
Key Points
- Cresemba's global in-market sales increased by 27% to USD693 million, demonstrating strong demand and market leadership.
- Zevtera was successfully launched in the US, with expectations for increased commercial uptake starting in the second quarter of 2026.
- Basilea Pharmaceutica Ltd (BPMUF) achieved a robust financial performance, with total revenue increasing by 11% to CHF232 million.
- The company significantly reduced its convertible debt to CHF76 million and tripled its net cash position.
- Basilea expanded its pipeline by in-licensing the Phase 3-ready asset ceftibuten-ledaborbactam, targeting a new market for complicated urinary tract infections.
- The anticipated loss of exclusivity for Cresemba in the US and Europe could impact revenues starting in 2027 and 2028, respectively.
- Increased research and development expenses are expected to rise by approximately 20% in 2026, reflecting higher investments in ongoing studies.
- The company faces potential challenges with the entry of generics for Cresemba, which could affect market share and revenue.
- Product revenue is expected to decrease due to reduced product supply to partners Pfizer and Gosun as they transition to manufacturing their own supply.
- The timeline for the Phase 3 program of ceftibuten-ledaborbactam is extended, with the study expected to start in early 2027 and readout in 2029.
Ladies and gentlemen, welcome to the Basilea Pharmaceutica full-year results 2025 conference call and live webcast. I am Mathilde, the Chorus Call operator. (Operator Instructions) And the conference is being recorded. (Operator Instructions) The conference must not be recorded for publication or broadcast.
At this time, it's my pleasure to hand over to David Veitch, Chief Executive Officer. Please go ahead.
Thank you. Hello. I'm David Veitch, CEO of Basilea, and I would like to welcome you to our conference call and webcast, presenting our financial results and key achievements for the full-year 2025, and as well as highlighting our priorities and future value drivers for 2026 and beyond. For further detailed information, please see the ad hoc announcement issued this morning and also our annual report. These documents are both available on our website at basilea.com.
I would like to mention that this call contains forward-looking
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
